5-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-N-[4-(trifluoromethyl)phenyl]pentanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-N-[4-(trifluoromethyl)phenyl]pentanamide
• 化学式: C₂₁H₂₃F₃N₂O₃
• 分子量: 408.4
• InChiKey: MXKRTZJQTHTYGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  59.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Serotonin 5HT1A and 5HT1D antagonists
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0478954A1

  公开（公告）日：1992-04-08

  The present invention is directed to a new class of serotonin 5HT1A agonists and pharmaceutical compositions containing them.

  本发明涉及一类新的血清素 5HT1A 激动剂和含有它们的药物组合物。
• Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of neoplasia
  申请人：Masferrer L. Jaime

  公开号：US20050085477A1

  公开（公告）日：2005-04-21

  The present invention provides compositions and methods for the treatment of neoplasia in a subject. More particularly, the invention provides a combination therapy for the treatment of a neoplasia comprising the administration to a subject of a serotonin modulating agent in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了用于治疗受试者肿瘤的组合物和方法。更具体地说，本发明提供了一种治疗肿瘤的组合疗法，包括向受试者施用5-羟色胺调节剂与环氧化酶-2选择性抑制剂。
• Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage
  申请人：Stephenson T. Diane

  公开号：US20050080084A1

  公开（公告）日：2005-04-14

  The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a serotonin-modulating agent in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了治疗受试者中枢神经系统损伤的组合物和方法。更具体地说，本发明提供了一种用于治疗中枢神经系统缺血性疾病或中枢神经系统创伤性损伤的组合疗法，该疗法包括向受试者施用血清素调节剂与环氧化酶-2 选择性抑制剂。
• Serotonin 5HT1A and 5HT1D agonists
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0478954B1

  公开（公告）日：2000-10-18
• COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA
  申请人：Pharmacia Corporation

  公开号：EP1660079A2

  公开（公告）日：2006-05-31